FARA accepts LOIs for its Kyle Bryant Translational Research Award, focusing on pre-clinical and clinical investigations that will advance treatments for FA. The specific aims must target one or more of the following:
- Identification of biomarkers for FA that will elucidate disease variability, severity, and prognosis; facilitate drug screening, and/or optimize selection of patients and clinical endpoints for clinical trials;
- Development of tools and technologies that can (a) be directly used for therapy development; (b) overcome existing obstacles to treatment and (c) be directly applied to, or adapted for, delivery of potential therapeutics;
- Pre-clinical development and testing of potential therapeutics, biologics, and devices in cells and animals;
- Clinical studies of patient outcome measures, potential interventions, or devices.
The deadline for the LOI is May 15. For those invited to submit a full application, the deadline for submission is July 15. On the Main Grant Page, put “KB Translational Award” in the “Grant Type” field. The applicant may request a budget of up to $250,000 per year for one or two years.